Ashland (ASH) investor relations material

Executive summary

• Q1 results were solid with steady execution and cost discipline, despite ongoing demand softness in coatings and construction, operational challenges, and isolated disruptions; net loss improved to $12 million from $165 million, driven by the absence of large impairment charges and improved performance.

• Life Sciences achieved healthy growth, driven by resilient pharma demand and innovation; Personal Care remained stable with double-digit growth in biofunctional actives, while Specialty Additives and Intermediates faced muted demand but benefited from cost actions.

• Early Q2 sales trends are encouraging, with resilience in key segments and solid free cash flow despite weather and operational disruptions.

• Exited the quarter with improving momentum, particularly in December and January.

Financial highlights

• Q1 sales were $386 million, down 5% year-over-year, mainly due to lower volume, Avoca divestiture, and pricing pressure; excluding Avoca, sales declined 3%.

• Adjusted EBITDA was $58 million, down 5% year-over-year, with a 15% margin; excluding Avoca, down 3%.

• Adjusted EPS (ex-intangible amortization) was $0.26, down 7% year-over-year; gross profit margin improved by 120 bps to 29.3%.

• Operating cash flow was $125 million, aided by a $103 million tax refund; free cash flow $26 million, with nearly 50% conversion.

• Liquidity at quarter-end was ~$900 million; net debt $1.1 billion; net leverage 2.7x.

Outlook and guidance

• Fiscal 2026 adjusted EBITDA guidance narrowed to $400–$420 million; sales guidance $1,835–$1,905 million.

• Double-digit-plus adjusted EPS growth targeted; ongoing free cash flow conversion expected at ~50% of adjusted EBITDA, with $100 million capex.

• Calvert City and weather disruptions to impact Q2 by ~$11 million, with most recovery expected in Q3 and Q4.

• Life Sciences and Personal Care expected to remain resilient; Specialty Additives and Intermediates to see gradual, regionally uneven recovery.

• Prudent approach to inventory and production management, with focus on long-term value creation.